Novogene(SH:688315) Xin Lang Cai Jing·2025-11-24 01:36Core Insights - On November 21, 2023, Nuohe Zhiyuan's stock fell by 4.01%, with a trading volume of 70.51 million yuan [1] - The company reported a financing buy-in of 7.14 million yuan and a financing repayment of 8.28 million yuan, resulting in a net financing outflow of 1.14 million yuan [1] - As of November 21, the total margin balance for Nuohe Zhiyuan was 130 million yuan, which is 2.33% of its market capitalization [1] Financing Summary - On the same day, the financing buy-in was 7.14 million yuan, with a current financing balance of 130 million yuan, exceeding the 60th percentile level over the past year [1] - The margin trading showed a repayment of 300 shares and a sell-out of 400 shares, with a sell-out amount of 5,356 yuan [1] - The margin balance was 136,500 yuan, which is below the 30th percentile level over the past year [1] Company Overview - Nuohe Zhiyuan, established on March 15, 2011, and listed on April 13, 2021, is located in Beijing and provides gene testing and bioinformatics analysis services [1] - The company's revenue composition includes: sequencing platform services (50.03%), life sciences basic research services (34.05%), medical research and technology services (13.37%), and others (2.54%) [1] Financial Performance - As of September 30, 2023, Nuohe Zhiyuan reported a total revenue of 1.581 billion yuan for the first nine months of 2023, representing a year-on-year growth of 4.05% [2] - The net profit attributable to shareholders was 113 million yuan, showing a year-on-year decrease of 16.05% [2] Shareholder Information - As of September 30, 2023, the number of shareholders was 9,680, a decrease of 1.24% from the previous period [2] - The average number of circulating shares per person increased by 1.26% to 42,995 shares [2] - Cumulative cash dividends since the A-share listing amount to 82.47 million yuan, with 58.45 million yuan distributed in the last three years [3]